Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
07:31am, Monday, 16'th Jun 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm
Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC trimmed its stake in Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 51.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutiona
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Friday, 06'th Jun 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript
09:30pm, Thursday, 15'th May 2025
Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
06:16pm, Thursday, 15'th May 2025
Gossamer Bio (GOSS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Wednesday, 07'th May 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
04:01pm, Wednesday, 07'th May 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Tuesday, 08'th Apr 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates
06:10pm, Thursday, 13'th Mar 2025
Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
04:01pm, Thursday, 13'th Mar 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Friday, 07'th Mar 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
07:42pm, Thursday, 13'th Feb 2025
Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far prod
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Friday, 07'th Feb 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
07:01am, Monday, 03'rd Feb 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
